Cancer Rehabilitation May Be Appropriate for Every Type of Cancer

Commentary
Video

Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.

Cancer prehabilitation is an understudied area of interest for Jessica Cheng, MD, where she hopes to make strides with upcoming trials.

Specifically, her research will focus on studying patients with breast and gynecologic cancers who are receiving chemotherapy but have not yet undergone surgery. She hopes that working with patients at this time point will allow them to become as fit as possible, which may improve outcomes after surgery and further treatment.

Cheng, assistant clinical professor in the Department of Supportive Care Medicine at City of Hope, noted she is currently designing a trial for these populations and hopes that this research may allow patients to have more control over their diseases.

Transcript:

Cancer rehabilitation applies to all patients with any type of cancer [or] anyone with a body. Overall, because this field is on the more recent side with not too many specialists, there’s a lot of room for research in every disease type and every stage of disease. Personally, my interest is in cancer prehabilitation. The research has exploded exponentially and become an international phenomenon over the last 10 years.

This is something very recent, and I’m working on designing a trial for patients with breast cancer and gynecologic [cancers] who are undergoing chemotherapy before surgery so that we can catch them at the earliest time point. [This may allow us to] make them as fit as possible in their mind and body at the earliest point to give them the best chance with their cancer treatment. There has been a recent study that showed that in patients who are undergoing neoadjuvant chemotherapy for breast cancer, the [patients] who did an exercise and nutrition training program were able to achieve a good outcome with pathologic complete response in 53% of the cases vs 28% of people who did not do the program. [I had] a lot of times talking with patients about [how] chemotherapy is not an excuse to not do exercise. It should be your push to exercise with all that you have in you to help the chemotherapy potentially work better. It’s a way that they can have a measure of control over their cancer journey.

Reference

Sanft T, Harrigan M, McGowan C, et al. Randomized trial of exercise and nutrition on chemotherapy completion and pathologic complete response in women with breast cancer: the lifestyle, exercise, and nutrition early after diagnosis study. J Clin Oncol. 2023;41(34):5285-5295. doi:10.1200/JCO.23.00871

Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.